Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

OBJECTIVE: In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population....

Descripción completa

Detalles Bibliográficos
Autores principales: González Martín, Antonio, Oza, Amit M., Embleton, Andrew C., Pfisterer, Jacobus, Ledermann, Jonathan A., Pujade-Lauraine, Eric, Kristensen, Gunnar, Bertrand, Monique A., Beale, Philip, Cervantes, Andrés, Kent, Emma, Kaplan, Richard S., Parmar, Mahesh K.B., Scotto, Nana, Perren, Timothy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338677/
https://www.ncbi.nlm.nih.gov/pubmed/30449719
http://dx.doi.org/10.1016/j.ygyno.2018.08.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338677/
https://www.ncbi.nlm.nih.gov/pubmed/30449719
http://dx.doi.org/10.1016/j.ygyno.2018.08.036

Ejemplares similares